Published by Josh White on 19th August 2019
(Sharecast News) - Immunotherapy developer Scancell announced the initiation of and further updates to the 'SCIB1' phase 2 trial in patients with metastatic melanoma also receiving the checkpoint inhibitor 'pembrolizumab' (Keytruda) on Monday.
URL: http://www.digitallook.com/dl/news/story/29454520/...